These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 443660)

  • 21. Drug hepatotoxicity from a regulatory perspective.
    Senior JR
    Clin Liver Dis; 2007 Aug; 11(3):507-24, vi. PubMed ID: 17723917
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New drugs with novel therapeutic characteristics. Have they been subject to randomized controlled trials?
    Lexchin J
    Can Fam Physician; 2002 Sep; 48():1487-92. PubMed ID: 12371307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A method for post-marketing screening of adverse reactions to drugs: initial results.
    Knapp DE; Zax BB; Rossi AC; O'Neill RT
    Drug Intell Clin Pharm; 1980 Jan; 14(1):23-7. PubMed ID: 10245773
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonprescription drugs: an overview.
    Hodes B
    Int J Health Serv; 1974; 4(1):125-30. PubMed ID: 4829892
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacovigilance in China: development and challenges.
    Zhao Y; Wang T; Li G; Sun S
    Int J Clin Pharm; 2018 Aug; 40(4):823-831. PubMed ID: 30051225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of the impact of scheduled postmarketing safety summary analyses on regulatory actions.
    Sekine S; Pinnow EE; Wu E; Kurtzig R; Hall M; Dal Pan GJ
    Clin Pharmacol Ther; 2016 Jul; 100(1):102-8. PubMed ID: 26853718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Premarketing adverse drug experiences: data management procedures. Unexpected death occurring early in clinical trials.
    Cato A
    Drug Inf J; 1987; 21(1):3-7. PubMed ID: 10281637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PathFX provides mechanistic insights into drug efficacy and safety for regulatory review and therapeutic development.
    Wilson JL; Racz R; Liu T; Adeniyi O; Sun J; Ramamoorthy A; Pacanowski M; Altman R
    PLoS Comput Biol; 2018 Dec; 14(12):e1006614. PubMed ID: 30532240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review of marketed medicinal products: review procedures in Finland and Norway.
    Idänpään-Heikkilä J
    Agents Actions; 1978 Jun; 8(4):414-7. PubMed ID: 98975
    [No Abstract]   [Full Text] [Related]  

  • 30. [Pharmacovigilance idea should be introduced sufficiently into the safety monitoring and evaluation process of Chinese drugs].
    Zhang L; Yang XH
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2009 Sep; 29(9):843-6. PubMed ID: 19960988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Controlling new drugs under marketing regulations.
    Hughes B; Winstock AR
    Addiction; 2012 Nov; 107(11):1894-9. PubMed ID: 22288473
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug policy: making effective drugs available without bankrupting the healthcare system.
    Laupacis A; Anderson G; O'Brien B
    Healthc Pap; 2002; 3(1):12-30. PubMed ID: 12811107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Measuring the efficacy of antiepileptic drugs.
    Mohanraj R; Brodie MJ
    Seizure; 2003 Oct; 12(7):413-43. PubMed ID: 12967570
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends.
    Issa AM; Phillips KA; Van Bebber S; Nidamarthy HG; Lasser KE; Haas JS; Alldredge BK; Wachter RM; Bates DW
    Curr Drug Saf; 2007 Sep; 2(3):177-85. PubMed ID: 18690965
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rethinking statistical approaches to evaluating drug safety.
    Liu JP
    Yonsei Med J; 2007 Dec; 48(6):895-900. PubMed ID: 18159580
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety Profile of Eslicarbazepine Acetate as Add-On Therapy in Adults with Refractory Focal-Onset Seizures: From Clinical Studies to 6 Years of Post-Marketing Experience.
    Gama H; Vieira M; Costa R; Graça J; Magalhães LM; Soares-da-Silva P
    Drug Saf; 2017 Dec; 40(12):1231-1240. PubMed ID: 28752473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using Data from the Canadian Post-marketing Spontaneous Pharmacovigilance System for Drug Safety Research: A Feasibility Study.
    Akinola S; da Silveira CG; Corbin S; Lavallée M; Thibault M; Gonella J; Gimenes FRE; Leclerc J
    Pharmaceut Med; 2020 Aug; 34(4):263-269. PubMed ID: 32671791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post-marketing surveillance of licensed medicinal and other products.
    Griffin JP
    Health Trends; 1981 Aug; 13(3):85-8. PubMed ID: 10258571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Auditing the drug regulator.
    Venning GR
    Lancet; 1984 May; 1(8387):1186. PubMed ID: 6144913
    [No Abstract]   [Full Text] [Related]  

  • 40. Post-marketing surveillance.
    Culliton BJ; Waterfall WK
    Br Med J; 1980 May; 280(6224):1175-6. PubMed ID: 7388453
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.